SFA Therapeutics Announces FDA Clearance for Amendment to Extend Phase Ib Trial of SFA-002 for Psoriasis

SFA Therapeutics, Inc.announced that it has received clearance from the US FDA to proceed with an extension to the ongoing Phase Ib clinical trial of SFA-002, an investigational drug candidate for psoriasis.